Promomed's revenue for 3 months of 2026 amounted to ₽7.3 billion, an increase of 62.2%, which is more than five times higher than the growth rate of the pharmaceutical market, which was 12% according to IQVIA. In the Endocrinology segment, revenue increased threefold to ₽4.8 billion. In the Oncology segment, sales decreased by 45% to ₽0.7 billion due to gove...

Board of Directors of Promomed recommended that dividends be paid for 3 months 2026 in the amount of ₽8 per ordinary share. The last day of the purchase of securities to receive dividends is June 18, 2026. Dividend yield may amount to 2.01%.

Promomed has started producing skincare products and dietary supplements under the Telomerol brand based on the telomeric theory of aging, which suggests that telomerase activation can slow down cellular aging. Line includes anti-aging face and eye creams, a lifting serum, patches, a hair mask, shampoo, and follicle activation products.

Promomed has repaid its structural bonds by transferring ordinary shares to investors. As a result, the free float will increase from 6.7% to 8.5%, and the short-term debt will decrease by ₽1.6 billion.